Abstract：
In the US, the Food and Drug Administration (FDA) has indicated it might place restrictions on how the abortion drug mifepristone is distributed and who can prescribe it. Some possible restrictions include limiting prescription privileges to doctors performing surgical abortions and requiring certification for mifepristone\'s use. It is noted that such restrictions could hamper access to the medical abortion method when it receives final FDA approval. In view of this, abortion access advocates posed several questions on the FDA arguing the proposed restrictions. The executive director of the National Abortion Federation, Vicki Saporta stated that such restrictions would disqualify/qualify physicians and would even disqualify some providers of surgical services from offering services to women, thereby denying access to hundreds of thousands of women. In addition, Saporta considers that, while there is a need to make sure that physicians are educated in this method, it is important that as many women as possible who want access to the medication are able to have it.
摘要：
在美国,美国食品和药物管理局(FDA)表示,可能会对人工流产药物米非司酮的分发方式以及谁可以开处方进行限制.一些可能的限制包括将处方特权限制为进行手术流产的医生，并要求对米非司酮的使用进行认证。值得注意的是，当药物流产方法获得FDA的最终批准时，这种限制可能会妨碍药物流产方法的使用。鉴于此,堕胎准入倡导者对FDA提出了几个问题，认为拟议的限制。全国堕胎联合会执行主任,VickiSaporta表示，这种限制将取消医生的资格，甚至取消一些手术服务提供者向妇女提供服务的资格，从而拒绝接触数十万妇女。此外,Saporta认为,虽然需要确保医生接受这种方法的教育，重要的是，尽可能多的想要获得药物的妇女能够拥有它。
